Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 19

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 19
---
”). Pursuant to the Nasdaq Conditions, the Company shall demonstrate compliance with the Bid Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also required to satisfy the $2.5 million stockholders’ equity requirement of the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”) on or prior to the Extended Deadline, submit certain plans to Nasdaq and make certain disclosures. The Company intends to apply to transfer its listing to the Nasdaq Capital Market and expects the proceeds of this offering to contribute materially to the satisfaction of the Stockholders’ Equity Requirement. Warrant Issuances On December 23, 2024, the Company issued warrants to purchase an aggregate of 84,059 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January 6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of $5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. Such number of shares and the exercise prices give effect to the Reverse Stock Split (as defined below). Reverse Stock Split At 12:01 a.m. Eastern time on January 8, 2025, we effected a reverse stock split (the “Reverse Stock Split”) pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. Cash Balance On January 7, 2025, the Company reported that, as a result of the receipt of proceeds from the warrant issuances described above, as well as issuances of shares of Common Stock pursuant to the New Keystone Purchase Agreement from December 6, 2024 through January 6, 2025, the Company had a cash balance of approximately $5.463 million as of January 7, 2025. Summary Risk Factors Investing in our securities involves risks. If any of these risks actually occur, our business, financial condition and results of operations would likely be materially adversely affected. You should carefully consider all the information contained in this prospectus before